Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2022 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
AMLX on Nasdaq
Shares outstanding
109,540,561
Price per share
$16.55
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
112,308,316
Total reported value
$1,356,738,139
% of total 13F portfolios
0.01%
Share change
+2,442,746
Value change
+$21,421,387
Number of holders
178
Price from insider filings
$16.55
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +39% $198,938,502 +$61,477,681 16,468,419 +45% FMR LLC 31 Dec 2025
PERCEPTIVE ADVISORS LLC 8.2% -6.7% $121,662,640 +$14,650,251 8,952,365 +14% Perceptive Advisors LLC 30 Sep 2025
BlackRock, Inc. 7.1% +32% $94,027,246 +$34,623,342 7,783,648 +58% BlackRock, Inc. 31 Dec 2025
TCG Crossover GP II, LLC 5.7% $74,863,306 6,243,812 TCG Crossover GP II, LLC 31 Dec 2025
VANGUARD GROUP INC 5.3% +6.8% $70,123,337 +$6,416,437 5,804,912 +10% The Vanguard Group 31 Dec 2025
Commodore Capital LP 5.1% $89,213,500 5,650,000 Commodore Capital LP 10 Nov 2025
Point72 Asset Management, L.P. 2.6% -54% $38,074,233 -$26,039,432 2,801,636 -41% Point72 Asset Management, L.P. 30 Sep 2025
Adage Capital Management, L.P. 2.5% -64% $33,296,889 -$48,436,878 2,777,055 -59% Adage Capital Management, L.P. 31 Dec 2025
Panacea Innovation Ltd 2.6% $11,792,000 2,200,000 Panacea Venture Healthcare Fund II, L.P. 31 Dec 2024

As of 31 Dec 2025, 178 institutional investors reported holding 112,308,316 shares of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX). This represents 103% of the company’s total 109,540,561 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 16,518,419 +45% 0.01% $199,542,502
BlackRock, Inc. 8.3% 9,054,431 +27% 0% $109,377,525
PERCEPTIVE ADVISORS LLC 7.6% 8,284,882 -7.5% 1.8% $100,081,375
TCG Crossover Management, LLC 5.7% 6,243,812 0% 2.5% $75,425,249
VANGUARD GROUP INC 5.3% 5,804,912 +10% 0% $70,123,336
Commodore Capital LP 5.2% 5,650,000 +39% 4.5% $68,252,000
Saturn V Capital Management LP 4.1% 4,496,487 -2.4% 10% $54,317,563
JANUS HENDERSON GROUP PLC 4.1% 4,465,872 +76% 0.02% $53,992,392
First Light Asset Management, LLC 3.1% 3,355,539 -0.01% 3.1% $40,534,911
Driehaus Capital Management LLC 2.8% 3,109,503 +28% 0.26% $37,562,796
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.5% 2,777,055 -59% 0.05% $33,546,824
GOLDMAN SACHS GROUP INC 2.4% 2,613,221 +30% 0% $31,567,709
MORGAN STANLEY 2.2% 2,359,824 +21% 0% $28,506,673
GEODE CAPITAL MANAGEMENT, LLC 2% 2,165,534 +20% 0% $26,163,536
Almitas Capital LLC 1.9% 2,122,597 0% 5.6% $25,640,972
STATE STREET CORP 1.9% 2,069,884 +28% 0% $25,004,199
GREAT POINT PARTNERS LLC 1.6% 1,750,000 +2.9% 6.9% $21,140,000
683 Capital Management, LLC 1.5% 1,650,000 -6.2% 1.7% $19,932,000
EVENTIDE ASSET MANAGEMENT, LLC 1.4% 1,513,148 +0.04% 0.29% $18,278,773
BANK OF AMERICA CORP /DE/ 1.2% 1,336,010 +211% 0% $16,139,001
DEUTSCHE BANK AG\ 1.2% 1,333,236 -2.4% 0.01% $16,105,491
FRANKLIN RESOURCES INC 1.1% 1,200,096 0% $14,497,160
Connor, Clark & Lunn Investment Management Ltd. 0.92% 1,004,021 -9.3% 0.03% $12,128,574
Logos Global Management LP 0.87% 950,000 -34% 0.76% $11,476,000
NORTHERN TRUST CORP 0.86% 937,764 +14% 0% $11,328,189

Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 112,308,316 $1,356,738,139 +$21,421,387 $12.08 178
2025 Q3 109,720,694 $1,491,122,082 +$396,029,872 $13.59 168
2025 Q2 81,690,006 $523,632,250 +$57,316,535 $6.41 131
2025 Q1 73,877,500 $261,528,744 +$85,099,354 $3.54 134
2024 Q4 49,784,011 $188,180,501 +$19,458,443 $3.78 120
2024 Q3 43,406,257 $140,608,833 +$5,128,506 $3.24 107
2024 Q2 43,632,024 $82,904,189 -$16,885,307 $1.90 115
2024 Q1 49,485,594 $140,539,742 -$234,955,037 $2.84 138
2023 Q4 60,281,638 $887,348,868 -$11,902,243 $14.72 177
2023 Q3 58,927,724 $1,078,966,869 +$84,065,478 $18.31 168
2023 Q2 54,545,075 $1,176,653,052 +$56,163,167 $21.57 153
2023 Q1 51,372,917 $1,507,231,117 +$73,671,274 $29.34 145
2022 Q4 48,572,530 $1,794,757,212 +$422,522,242 $36.95 131
2022 Q3 36,858,311 $1,037,561,470 +$315,174,073 $28.15 90
2022 Q2 26,621,859 $512,910,346 +$65,322,870 $19.26 74
2022 Q1 23,420,880 $299,935,403 +$299,912,422 $12.85 72